Patent US3078040A successfully refreshed from Google Patents.
Patent US5614487A successfully refreshed from Google Patents.
US5614487A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release pharmaceutical composition
Assignee: Genentech Inc
•
Filing: 1993-05-28
•
Granted: 1997-03-25
•
Expires: 2013-05-28
Abstract
Abstract The present document discloses the formation of imine adducts, preferably between a primary amine of a biologically active polypeptide and a reactive aldehyde group of a physiologically acceptable carrier. The imine adduct of human growth hormone and dextran is specifically described. These adducts serve to release the biologically active polypeptide via the reversible reaction in the formation of the imine adduct bond. These adducts have a surprising degree of stability that permits the use of the complex as a sustained release preparation. A key advantage of this technology is that after hydrolysis the complex releases the unmodified pharmaceutical. Thus, these adducts can be used as pharmaceutical compositions useful for the sustained release of the biologically active polypeptide over a predetermined, desired period of time.
Inventors
- 👤 John E. Battersby
- 👤 Ross G. Clark
- 👤 William S. Hancock
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 22:56
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/27; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/61
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
59 words
A sustained release pharmaceutical composition comprising a pharmaceutically acceptable excipient admixed with a sustained release pharmaceutical imine bond adduct of a dextran carrier and a biologically active polypeptide, wherein said imine bond is formed by reaction of a reactive aldehyde group with a primary amine under non-reducing conditions and wherein said biologically active polypeptide is hGH or N-methionyl hGH.
Claim 2
Dependent Claim
59 words
A sustained release pharmaceutical composition comprising a pharmaceutically acceptable excipient admixed with a sustained release pharmaceutical imine bond adduct of a dextran carrier and a biologically active polypeptide, wherein said imine bond is formed by reaction of a reactive aldehyde group with a primary amine under non-reducing conditions and wherein said biologically active polypeptide is hGH or N-methionyl hGH.
Claim 3
Dependent Claim
56 words
A sustained release pharmaceutical composition comprising a pharmaceutically acceptable excipient admixed with a sustained release pharmaceutical imine bond adduct of a dextran carrier and a biologically active polypeptide, wherein said imine bond is formed by reaction of a reactive aldehyde group with a primary amine under non-reducing conditions and wherein said biologically active polypeptide is IGF-1.
Claim 4
Dependent Claim
56 words
A sustained release pharmaceutical composition comprising a pharmaceutically acceptable excipient admixed with a sustained release pharmaceutical imine bond adduct of a dextran carrier and a biologically active polypeptide, wherein said imine bond is formed by reaction of a reactive aldehyde group with a primary amine under non-reducing conditions and wherein said biologically active polypeptide is IGF-1.
Claim 5
Dependent Claim
56 words
A sustained release pharmaceutical composition comprising a pharmaceutically acceptable excipient admixed with a sustained release pharmaceutical imine bond adduct of a dextran carrier and a biologically active polypeptide, wherein said imine bond is formed by reaction of a reactive aldehyde group with a primary amine under non-reducing conditions and wherein said biologically active peptide is t-PA.
Claim 6
Dependent Claim
56 words
A sustained release pharmaceutical composition comprising a pharmaceutically acceptable excipient admixed with a sustained release pharmaceutical imine bond adduct of a dextran carrier and a biologically active polypeptide, wherein said imine bond is formed by reaction of a reactive aldehyde group with a primary amine under non-reducing conditions and wherein said biologically active peptide is t-PA.
References Cited (Backward Citations)
US4003792A
Cited
US4179337A
Cited
US3947352A
Cited
US4446316A
Cited
US4452773A
Cited
US4585754A
Cited
US4745180A
Cited
US4857505A
Cited
WO1990001332A1
Cited
EP0372752A2
Cited
US5130255A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-03-24 | 2000-09-23 | 2001-03-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-03-24 | 2004-09-23 | 2005-03-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-03-24 | 2008-09-23 | 2009-03-25 | $7700.00 | Window Closed / Lapsed |